We are live on ! Find out more
EAM

Erste Asset Management Portfolio holdings

AUM $12.9B
1-Year Est. Return 52.69%
This Fund
S&P 500
This Quarter Est. Return
+27.29%
1 Year Est. Return
+52.69%
3 Year Est. Return
+142.55%
5 Year Est. Return
+182.36%
10 Year Est. Return
AUM
$12.9B
AUM Growth
+$2.07B
Cap. Flow
+$215M
Cap. Flow %
1.67%
Top 10 Hldgs %
29.08%
Holding
680
New
78
Increased
215
Reduced
198
Closed
77

Top Buys

Rank Stock Value
1
AVGO icon
Broadcom
AVGO
+$144M
2
MSFT icon
Microsoft
MSFT
+$121M
3
JPM icon
JPMorgan Chase
JPM
+$82.8M
4
DVN icon
Devon Energy
DVN
+$63.8M
5
NVDA icon
NVIDIA
NVDA
+$62.2M

Top Sells

Rank Stock Value
1
CTAS icon
Cintas
CTAS
+$74.9M
2
LRCX icon
Lam Research
LRCX
+$69.5M
3
ADBE icon
Adobe
ADBE
+$67.6M
4
INTU icon
Intuit
INTU
+$60.7M
5
ON icon
ON Semiconductor
ON
+$52.5M

Sector Composition

Rank Sector Weight
1 Technology 38.4%
2 Healthcare 12.52%
3 Financials 10.05%
4 Communication Services 8.97%
5 Industrials 7.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MCK icon
326
McKesson
MCK
$104B
$3.42M 0.03%
4,573
-564
-11% -$447K
STLD icon
327
Steel Dynamics
STLD
$33.6B
$3.41M 0.03%
14,600
-2,226
-13% -$521K
ACAD icon
328
Acadia Pharmaceuticals
ACAD
$5.02B
$3.37M 0.03%
133,700
NBIX icon
329
Neurocrine Biosciences
NBIX
$15.7B
$3.35M 0.03%
19,700
ZBRA icon
330
Zebra Technologies
ZBRA
$16.9B
$3.3M 0.03%
+12,894
New +$3.03M
KRYS icon
331
Krystal Biotech
KRYS
$10.4B
$3.29M 0.03%
8,700
WBD icon
332
Warner Bros
WBD
$72.1B
$3.19M 0.02%
117,586
+21,347
+22% +$578K
APGE icon
333
Apogee Therapeutics
APGE
$10.2B
$3.18M 0.02%
24,000
IRM icon
334
Iron Mountain
IRM
$35B
$3.12M 0.02%
24,000
+1,000
+4% +$123K
WSM icon
335
Williams-Sonoma
WSM
$27.7B
$3.1M 0.02%
+12,900
New +$2.56M
WAT icon
336
Waters Corp
WAT
$40.7B
$3.07M 0.02%
8,268
-3,078
-27% -$1.05M
XENE icon
337
Xenon Pharmaceuticals
XENE
$5.81B
$3.01M 0.02%
50,000
SBUX icon
338
Starbucks
SBUX
$123B
$3M 0.02%
26,842
-481
-2% -$48.4K
TOST icon
339
Toast
TOST
$20.3B
$2.98M 0.02%
105,997
+3,997
+4% +$104K
XBI icon
340
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$2.97M 0.02%
23,130
KYMR icon
341
Kymera Therapeutics
KYMR
$9.82B
$2.95M 0.02%
27,000
MHK icon
342
Mohawk Industries
MHK
$8.8B
$2.91M 0.02%
24,519
+919
+4% +$96.6K
OSK icon
343
Oshkosh
OSK
$9.51B
$2.87M 0.02%
18,666
-2,285
-11% -$322K
AFL icon
344
Aflac
AFL
$58.4B
$2.85M 0.02%
23,772
-464
-2% -$53.4K
EXEL icon
345
Exelixis
EXEL
$13.5B
$2.85M 0.02%
52,500
ACGL icon
346
Arch Capital
ACGL
$33.7B
$2.82M 0.02%
28,830
+11,500
+66% +$1.08M
NSC icon
347
Norfolk Southern
NSC
$78.3B
$2.77M 0.02%
8,763
+4,704
+116% +$1.45M
CDE icon
348
Coeur Mining
CDE
$21.7B
$2.75M 0.02%
168,264
VEEV icon
349
Veeva Systems
VEEV
$44.8B
$2.72M 0.02%
15,381
+596
+4% +$98.3K
KAI icon
350
Kadant
KAI
$3.57B
$2.69M 0.02%
8,589
-16,799
-66% -$5.23M

Similar funds

Erste Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Erste Asset Management held 680 positions worth $12.9B, up 19% from $10.8B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Erste Asset Management's Q2 2026 filing shows 78 new, 215 increased, 198 reduced and 77 closed positions. Its largest new stake was IDEX: 150,090 shares worth $33.9M. The largest sale was Cintas, an estimated $74.9M.

By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 33% a quarter earlier, followed by Healthcare and Financials.

  • Erste Asset Management's largest Q2 2026 buy was IDEX: 150,090 shares worth $33.9M.
  • Erste Asset Management added most to Broadcom in Q2 2026, an estimated $144M increase.
  • Erste Asset Management's biggest Q2 2026 reduction was Cintas, cutting an estimated $74.9M.
  • Erste Asset Management fully exited Coterra Energy in Q2 2026, selling an estimated $41.1M.
  • Erste Asset Management's ten largest holdings make up 29% of its $12.9B portfolio in Q2 2026.
  • Erste Asset Management opened 78 new positions and closed 77 in Q2 2026.
  • Erste Asset Management's portfolio value rose 19% quarter-over-quarter to $12.9B.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.